Department of Genomic Drug Discovery Science, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-20 Yoshida Shimoadachi-cho Sakyo-ku, Kyoto 606-8501, Japan.
BMC Genomics. 2010 Feb 25;11:137. doi: 10.1186/1471-2164-11-137.
Cancer cells undergo massive alterations to their DNA methylation patterns that result in aberrant gene expression and malignant phenotypes. However, the mechanisms that underlie methylome changes are not well understood nor is the genomic distribution of DNA methylation changes well characterized.
Here, we performed methylated DNA immunoprecipitation combined with high-throughput sequencing (MeDIP-seq) to obtain whole-genome DNA methylation profiles for eight human breast cancer cell (BCC) lines and for normal human mammary epithelial cells (HMEC). The MeDIP-seq analysis generated non-biased DNA methylation maps by covering almost the entire genome with sufficient depth and resolution. The most prominent feature of the BCC lines compared to HMEC was a massively reduced methylation level particularly in CpG-poor regions. While hypomethylation did not appear to be associated with particular genomic features, hypermethylation preferentially occurred at CpG-rich gene-related regions independently of the distance from transcription start sites. We also investigated methylome alterations during epithelial-to-mesenchymal transition (EMT) in MCF7 cells. EMT induction was associated with specific alterations to the methylation patterns of gene-related CpG-rich regions, although overall methylation levels were not significantly altered. Moreover, approximately 40% of the epithelial cell-specific methylation patterns in gene-related regions were altered to those typical of mesenchymal cells, suggesting a cell-type specific regulation of DNA methylation.
This study provides the most comprehensive analysis to date of the methylome of human mammary cell lines and has produced novel insights into the mechanisms of methylome alteration during tumorigenesis and the interdependence between DNA methylome alterations and morphological changes.
癌细胞的 DNA 甲基化模式发生了大量改变,导致异常的基因表达和恶性表型。然而,甲基化组变化的机制尚不清楚,也没有很好地描述 DNA 甲基化变化的基因组分布。
在这里,我们进行了甲基化 DNA 免疫沉淀结合高通量测序(MeDIP-seq),以获得 8 个人乳腺癌细胞(BCC)系和正常人类乳腺上皮细胞(HMEC)的全基因组 DNA 甲基化图谱。MeDIP-seq 分析通过以足够的深度和分辨率覆盖几乎整个基因组,生成了无偏的 DNA 甲基化图谱。与 HMEC 相比,BCC 系最显著的特征是甲基化水平大幅降低,特别是在 CpG 贫乏区域。虽然低甲基化似乎与特定的基因组特征无关,但高甲基化优先发生在 CpG 丰富的基因相关区域,而与转录起始位点的距离无关。我们还研究了 MCF7 细胞上皮间质转化(EMT)过程中的甲基组改变。EMT 诱导与基因相关的 CpG 丰富区域的甲基化模式的特定改变相关,尽管总体甲基化水平没有显著改变。此外,基因相关区域上皮细胞特异性甲基化模式的大约 40%被改变为间质细胞特有的模式,表明 DNA 甲基化受到细胞类型特异性调节。
本研究提供了迄今为止对人乳腺细胞系甲基组的最全面分析,并对肿瘤发生过程中甲基组改变的机制以及 DNA 甲基化改变与形态变化之间的相互依赖关系产生了新的认识。